Abstract
Selecting the most appropriate dosing time of PD-1/PD-L1 inhibitors may aid in developing cancer immunotherapy with higher efficacy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1158/1541-7786.mcr-21-0786
Journal: Cell Growth & Differentiation | Publication Date: Feb 21, 2022 |
Citations: 27 | License type: CC BY-NC-ND 4.0 |
Selecting the most appropriate dosing time of PD-1/PD-L1 inhibitors may aid in developing cancer immunotherapy with higher efficacy.
Join us for a 30 min session where you can share your feedback and ask us any queries you have